Abbreviations
Graves ophthalmopathy (GO) is an autoimmune disease that typically affects the thyroid gland and the orbit. The roles of the thyroid stimulating hormone receptor and cellular and humoral immunity in the pathogenesis of GO are being investigated. Investigators are gaining insights into the epidemiology of GO as it relates to other ocular and autoimmune diseases. Several possible tools for assessing GO disease activity are being studied. Medical and radiation therapy for GO recently have been evaluated prospectively. Orbital surgeons continue to refine orbital decompression techniques to improve patient outcomes and minimize surgical complications. Graves ophthalmopathy (GO) continues to challenge basic scientists who study the pathophysiology of the disease and clinicians who care for patients with GO. Modest advances have been made recently in understanding the immunologic and genetic basis of the disease. Case series data continue to serve as the basis for much of the care offered to patients with GO, although clinical trials evaluating therapies for GO are emerging. Although this review will briefly highlight the most important basic scientific advances in understanding GO, its emphasis is primarily on recent clinical advances in treating GO.
Pathogenesis
Graves ophthalmopathy is generally considered to be an autoimmune disease, with the thyroid stimulating hormone (TSH) receptor the likely autoantigen in both the orbit and the thyroid gland [1]. Thyroid stimulating hormone receptor mRNA has been detected in orbital fat specimens [2] , and recent studies have shown the intact protein on orbital fat cells from patients with GO [3]. Antibodies to the TSH receptor have been speculated to play a role in the pathogenesis of GO by stimulating orbital fibroblasts to produce glycosaminoglycans. Several investigators are evaluating the roles of various cytokines in glycosaminoglycan production and adipogenesis [4-7]. The resulting extraocular muscle enlargement and orbital fat compartment expansion lead to the features that characterize GO: restrictive myopathy, eyelid retraction, proptosis, and compressive optic neuropathy.
Recent evidence suggests that cellular immunity also may be important in the pathogenesis of GO. Pappa et al. biopsied the extraocular muscles of 5 patients with early GO, 9 patients with late GO, and 14 normal subjects [8•]. They detected an increased number of T-cells and macrophages in the early GO specimens compared with either the late GO or normal control biopsies. Although the study was performed on only a small number of early GO specimens, and the biopsies were not reviewed in a masked fashion, the results may suggest a greater role for cell-mediated immunity in GO than has been appreciated previously. The relative primacy of humoral or cellmediated immunity in the pathogenesis of GO remains to be determined [9] . Our current understanding of the immune, genetic, and environmental factors that impact Graves thyroid and eye disease is outlined in a recent review [10••]. pothyroidism, a small portion of patients with GO do not display systemic thyroid dysregulation. Previous studies estimated the prevalence of euthyroid GO to be 6 to 21% in patients with GO [11, 12] . A recent study, however, indicates that more sensitive assays for thyroid hormone concentrations may be able to detect hyperthyroidism in the vast majority of patients with GO [13] . Only 0.7% of patients in this study of 1020 Asian patients with GO were found to be euthyroid. The generalizability of this finding to the more heterogeneous US population is uncertain. In contrast to the low level of euthyroidism detected in this Asian study, a European group reported a 12.9% prevalence of euthyroid GO in patients with myasthenia gravis, compared with a 3.1% prevalence of euthyroid GO in patients without myasthenia [14] . Although the results obtained in this university clinicbased study may have been influenced in part by referral bias, they may prompt future population-based studies to address more rigorously whether euthyroidism is more prevalent in myasthenic patients with GO than in patients with GO who do not have myasthenia gravis.
The prevalence of open-angle glaucoma in patients with hyperthyroidism or GO recently was reported to be higher than previously considered [15•]. In their university-based practice, Ohtsuka et al. documented that 13% of patients had normal tension glaucoma and 22% had ocular hypertension. Limits of the study included the use of normative data from a general patient population for comparison with the tertiary care center-based patients with GO, and the inclusion of hyperthyroid patients in the study. Additionally, the study population was comprised of Japanese patients, and may therefore not be generalizable to U.S. patients. Nonetheless, clinicians should consider GO a possible risk factor for ocular hypertension and open angle glaucoma, and should monitor patients' intraocular pressure (IOP), optic nerve appearance, and visual fields accordingly.
Evaluating Graves ophthalmopathy disease activity and severity
Because patients with GO are felt to respond best to immunosuppressive therapy in the active inflammatory stage of the disease rather than the later fibrotic stage, investigators have sought a clinical marker than can distinguish active from inactive GO. Orbital ultrasonography, quantitative orbital magnetic resonance imaging (MRI), and assessment of saccadic velocity are unable to differentiate reliably between active and inactive GO [16] [17] [18] . High rates of interobserver and intraobserver variability in interpreting somatostatin-receptor scintigraphy limit the clinical applicability of this method of assessing clinical activity [19] .
Graves ophthalmopathy disease severity was evaluated radiographically by orbital MRI of 37 patients with GO [20]. Magnetic resonance imaging was shown to detect optic nerve compression effectively in these patients, but comparative data with computed tomography (CT) was not provided. Computed tomography remains the standard technique at many institutions for radiographic assessment of GO because of its ability to display bony orbital anatomy and its low cost relative to MRI. The relative superiority of MRI versus CT in estimating extraocular muscle (EOM) volume also remains to be determined. Accurate assessment of EOM size is necessary if EOM volume is to be used in either clinical trials or practice as a marker of treatment response. Although CT has been shown to be a useful tool to measure orbital volume [21, 22] , investigators recently have shown that MRI also can accurately assess EOM volume in GO [23].
The orbital vasculature in GO recently was assessed using color Doppler imaging [24] . The investigators detected several significant differences in orbital blood flow of GO patients compared with both normal controls and patients with systemic thyroid disease in the absence of ophthalmopathy. The clinical utility of this technique, as well as its ability to differentiate clinically active from inactive disease, remain issues for future study.
Because GO manifests as a complex constellation of symptoms and signs and is treated with therapies that carry significant potential side effects, no single measure can be used to assess disease severity and treatment outcome. In an effort to assess more comprehensively the impact of GO and its treatment on the patient's overall well being, investigators have developed a questionnaire to evaluate patient quality of life. The Graves Ophthalmopathy Quality of Life (GO-QOL) instrument is a Dutch language instrument that has been shown to be reliable in a Dutch population [25, 26] . Terwee et al. [27] recently reported changes in patient GO-QOL scores in response to orbital decompression, strabismus surgery, and eyelid surgery. The GO-QOL instrument is not yet applicable for clinical or research practice in the US because an American English language version of the instrument has not been developed and evaluated.
Medical treatment
Although corticosteroids commonly are prescribed for clinically active GO, their many side effects limit their long-term usefulness. Speculating that antioxidant therapy might be effective against GO, Bouzas et al. conducted a prospective, nonrandomized clinical trial of allopurinol and nicotinamide versus placebo in 22 tobacco smokers with GO [28•]. Change in "NOSPECS" disease severity score was evaluated as the primary outcome. The authors reported that 9 of 11 patients in the treatment group improved, compared with 3 of 11 patients in the placebo group. Although the study is limited by its nonrandomized design and by the use of the widelycriticized NOSPECS system as a treatment endpoint, it may prompt future prospective randomized clinical trials of antioxidant agents.
Radiation treatment
Orbital radiation is used widely to treat the compressive optic neuropathy and the orbital inflammatory signs associated with GO. A recent study confirms prior case series data by reporting good efficacy of orbital radiation in treating compressive optic neuropathy [29] . In this retrospective, uncontrolled case series with four months of follow-up, the authors report that 8 of 10 GO patients treated with 2000 cGy showed improved optic nerve function after radiation therapy. Although the authors did not provide statistical analysis, their descriptive data indicate that mean visual acuity improved modestly from 20/30 before treatment to 20/20 after treatment. Color vision and peripheral visual field measures also improved.
The efficacy of orbital radiation in treating GO-associated orbital edema, myopathy, and proptosis was evaluated in two retrospective case series, with conflicting results. Tsujino et al. [30] reported that 68% of their 121 patients had a "good" or "excellent" response to orbital radiation, as assessed by NOSPECS criteria. However, the concomitant use of systemic steroids in 86 of these patients may have confounded their results. In contrast, Van Ruyven et al. [31] were not able to detect a clinically significant improvement in NOSPECS score in the 90 patients that comprised their case series.
Fortunately, a recent randomized clinical trial has evaluated more rigorously the efficacy of orbital radiation for GO. Mourits et al. [32••] randomly assigned 60 patients with moderately severe GO to receive either 2000 cGy orbital radiation or sham irradiation. Patients with compressive optic neuropathy were excluded from the study. Treatment outcomes were measured by major and minor criteria. Major criteria included improvement of eye movement by more than 8 degrees in any direction, or improvement in diplopia grade (eg, from diplopia in primary position to diplopia in extremes of gaze only). Minor criteria were change in interpalpebral fissure height of Ն 2 mm, change in proptosis Ն 2 mm, or change in eyelid swelling. Improvement in one major or two minor criteria defined successful treatment. The authors found that 82% of patients treated with radiation had improvement of eye movement by more than 8 degrees in any direction, compared with 27% of patients who received sham irradiation. However, most patients with severe diplopia did not gain enough single binocular vision to avoid strabismus surgery after orbital radiation. Additionally, no differences in palpebral fissure height, proptosis, or eyelid swelling were noted between the two groups. Therefore, the authors concluded that orbital radiation is only indicated to treat motility impairment. However, even in the setting of motility impairment, the clinical benefit of orbital radiation may be modest (as evidenced by the need for strabismus surgery) in most patients with severe diplopia, despite measurable improvement in ocular range of motion. Finally, the study's randomization produced unequal treatment groups, with the radiation therapy group containing more male smokers with severe diplopia compared with the sham radiation group. The motility improvement attributed to radiation may simply reflect regression toward the mean in the more severely affected radiation patients. The lack of efficacy of radiation therapy for moderately severe GO is further supported in a forthcoming randomized trial of orbital radiation versus sham irradiation in which no significant improvement was detected in any parameter measured [33] .
Surgical treatment
Multiple routes can be taken to decompress the bony socket by removing orbital bone and fat. The superiority of one method over others has not been established. However, several authors have added their case series to the surgical decompression literature. A two-wall orbital decompression can be achieved through a transcaruncular approach to the medial orbital wall and the orbital floor [34•] . Transantral decompression also achieves a two-wall decompression by traversing the maxillary sinus to remove the medial orbital wall and the orbital floor. Tallstedt et al. [35] confirmed previous reports of a high incidence of postoperative diplopia associated with this technique in their series of 63 patients. Of the 43 patients who had single binocular vision preoperatively, 22 (51%) had diplopia postoperatively. Additionally, half of patients reported postoperative hypesthesia in the distribution of the infraorbital nerve, although many of these patients were not bothered severely by this symptom. Michel et al. [36] also reported high rates of postoperative diplopia in their case series of patients who underwent endoscopic transnasal orbital decompression. Of the 78 patients described in the series, 36 patients had single binocular vision preoperatively, but only 15 patients maintained single vision postoperatively. 58 of 78 patients required strabismus surgery.
A transconjunctival lateral wall decompression technique was described in a case series of 19 patients [37] . The authors achieved a mean 5.5 mm proptosis reduction, and report that the six cases involving compressive optic neuropathy improved with this lateral orbital approach. Unfortunately, visual function data are not presented on these six cases. The authors did note a low rate of postoperative diplopia, with only 2 of 16 patients affected. In an effort to compare the rates of postoperative diplopia after lateral wall decompression with "balanced" medial and lateral wall decompression, Goldberg et al. [38] report their results with the two techniques. In a nonrandomized case series, the authors did not show a significant difference in the incidence of induced diplopia with the different techniques.
The orbit also can be decompressed by orbital fat removal. Previous reports have indicated that proptosis can be reduced by approximately 2 mm by fat removal alone [39] . This technique also has been reported to treat optic neuropathy effectively in a case series of eight orbits in five patients, although postoperative treatment of four of the five patients with systemic corticosteroids may have contributed to their clinical improvement [40] .
The impact of orbital decompression, strabismus surgery, and orbital radiation on IOP in patients with GO was evaluated in a retrospective, uncontrolled study [41] . The authors found that IOP in primary position declined a mean 4.1 mm Hgin in patients with GO after orbital decompression, whereas strabismus surgery resulted in an average 2.4 mm Hg decrease in IOP. Radiation therapy had no effect on IOP.
A potential late complication of endoscopic orbital decompression was described by Remulla et al. [42] . Three patients who underwent endoscopic transnasal decompression developed orbital infection more than two years after surgery. The frontal sinus was the infection source in all three cases. Two of the three patients needed surgical treatment of the infection. To avoid this complication, the authors recommend that the anterosuperior portion of the lamina paprycea be left intact at the time of medial wall decompression to avoid encroaching on the region of the frontal recess.
Conclusion
Prospective controlled trials that critically evaluate medical and radiation treatment for GO are providing a scientific basis for the care of patients with GO. However, most care provided to these patients continues to be based on descriptive case series data or the instincts of individual clinicians. Future rigorous studies that evaluate the medical and surgical treatments offered to patients with GO are needed [43] . Until those studies are completed, supportive care, systemic corticosteroids, and surgical therapy remain the mainstay of GO treatment.
